NCT05438186View on ClinicalTrials.gov

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

WithdrawnOBSERVATIONAL

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

October 31, 2022

Conditions

Obesity

Interventions

DRUG

Liraglutide

Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.

Trial Locations (1)

Unknown

Novo Nordisk Investigational Site, Istanbul